TuHURA Biosciences, Inc./NV
About TuHURA Biosciences, Inc./NV
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$30.1M
- Total assets
- $27.4M
- Market cap
- $125.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $31.8M
- Income tax
- $1.6K
- Net income
- -$30.1M
- EPS (basic)
- $-0.63
- EPS (diluted)
- $-0.63
Balance sheet
- Total assets
- $27.4M
- Current assets
- $4.6M
- Total liabilities
- $6.4M
- Current liabilities
- $5.9M
- Shareholders’ equity
- $20.9M
Cash flow
- Operating cash flow
- -$27.6M
- Investing cash flow
- -$1.3M
- Financing cash flow
- $19.9M
- Net cash flow
- -$9.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $125.1M
- EPS (diluted)
- $-0.63
- Shares outstanding
- 61.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 18, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $30.1M in FY2025.
- Trading 50% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TuHURA Biosciences, Inc./NV.
Write a review
News about TuHURA Biosciences, Inc./NV
News & sentiment via Polygon.io
